SEC Form 424B5 filed by Aprea Therapeutics Inc.
(To prospectus dated February 2, 2024)
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-3 | | | |
| | | | | S-6 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-11 | | | |
| | | | | S-12 | | | |
| | | | | S-13 | | | |
| | | | | S-16 | | | |
| | | | | S-17 | | | |
| | | | | S-17 | | | |
| | | | | S-17 | | | |
| | | | | S-19 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 19 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 25 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 3.9717 | | |
|
Net tangible book value per share as of September 30, 2024
|
| | | $ | 4.03 | | | | | | | | |
|
Decrease in net tangible book value per share attributable to this offering
|
| | | $ | (0.08) | | | | | | | | |
|
As adjusted net tangible book value per share as of September 30, 2024, after giving effect to this offering
|
| | | | | | | | | $ | 3.95 | | |
|
Dilution per share to new investors purchasing shares in this offering
|
| | | | | | | | | $ | 0.0217 | | |
3805 Old Easton Road
Doylestown, PA 18902
(617) 463-9385
Preferred Stock
Warrants
Debt Securities
Rights to Purchase Common Stock, Preferred Stock,
Debt Securities or Units
Units
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 19 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 25 | | |
3805 Old Easton Road
Doylestown, PA 18902
(617) 463-9385